Kymera Therapeutics

Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Kymera Therapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Kymera Therapeutics balance sheet

Report period2018 2019 2020 2021 2022 2023
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Kymera Therapeutics cash flows

Report period2018 2019 2020 2021 2022 2023
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Kymera Therapeutics multipliers

Report period2018 2019 2020 2021 2022 2023
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Kymera Therapeutics profitability

Report period2018 2019 2020 2021 2022 2023
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Kymera Therapeutics assets
Kymera Therapeutics cash flows

Kymera Therapeutics shares

TickerNameTypeNominal valueISINPrice
KYMR:USKymera TherapeuticsCommon share-US5015751044$40.72
Kymera Therapeutics news
03.05.2022
Kymera Therapeutics' GAAP loss for 3 months of 2022 was $36.684 million, up 2.8 times from $13.075 million in the previous year. Revenue decreased by 48.6% to $9.622 million compared to $18.702 million a year earlier.
Source: {source} pictogram investors.kymeratx.com
Pictogram next
24.02.2022
Kymera Therapeutics' GAAP loss for 2021 was $100.217 million, up 2.2 times from $45.593 million in the previous year. Revenue increased 2.1 times to $72.832 million from $34.034 million a year earlier.
Source: {source} pictogram investors.kymeratx.com
Pictogram next
10.11.2021
Kymera Therapeutics reported a GAAP loss of $66.317 million for 9M 2021, doubling from $32.908 million in the previous year. Revenue increased 2.7 times to $57.557 million from $21.249 million a year earlier.
Source: {source} pictogram investors.kymeratx.com
Pictogram next
06.08.2021
Kymera Therapeutics' GAAP loss for six months of 2021 was $37.735 million, up 51.4% from $24.921 million in the prior year. Revenue increased 5.5 times to $37.221 million from $6.716 million a year earlier.
Source: {source} pictogram investors.kymeratx.com
Pictogram next
All Kymera Therapeutics news
General information
Company nameKymera Therapeutics
Business address300 TECHNOLOGY SQUARE 2ND FLOOR CAMBRIDGE MA 02139 857-285-5314
Mailing address300 TECHNOLOGY SQUARE 2ND FLOOR CAMBRIDGE MA 02139
Websitewww.kymeratx.com
Information disclosurewww.sec.gov